返回
COMPLEMENTing immunotherapy
DOI:10.1038/s43018-022-00442-6.png)
摘要
En 中文
Intratumoral activation of the complement cascade may have therapeutic potential in patients with lung cancer with strong EGFR signaling, shows a new study. EGFR-triggered expression of CD55 and CD59 prevents opsonization of tumor cells, inhibits antitumor immunity and confers resistance to immune-checkpoint inhibitors.
Keyword:
LUNG-CANCER
ACTIVATION
BLOCKADE
期刊
IF:
28.5
论文数:
1.3K
被引数:
1.3W
机构
引用论文
Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing cells in renal cell cancer三级淋巴结构在肾细胞癌中产生和传播抗肿瘤抗体产生细胞
IMMUNITY
IF26.3
Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression通过C3a受体途径激活补体可改变CD4 T淋巴细胞并介导肺癌进展
CANCER RESEARCH
IF16.6
Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade
NATURE CANCER
IF28.5
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
MOLECULAR CANCER
IF33.9
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New StrategiesEGFR突变肺癌的免疫治疗: 当前挑战与新策略
A Combined PD-1/C5a Blockade Synergistically Protects against Lung Cancer Growth and MetastasisPD-1/C5a联合阻断协同保护肺癌生长和转移
CANCER DISCOVERY
IF33.3

